Comparative Pharmacology
Head-to-head clinical analysis: SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE versus SULFATRIM DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE versus SULFATRIM DS.
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE vs SULFATRIM-DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide sodium inhibits bacterial dihydropteroate synthase, blocking folate synthesis; prednisolone sodium phosphate suppresses inflammation by binding glucocorticoid receptors, inhibiting phospholipase A2 and pro-inflammatory cytokine production.
Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, inhibiting reduction of dihydrofolate to tetrahydrofolate. Sequential blockade of folate metabolism exerts bactericidal effect.
1-2 drops into the conjunctival sac of the affected eye(s) every 2-4 hours during the day and at bedtime; frequency may be decreased as clinical signs improve.
One double-strength tablet (160 mg trimethoprim/800 mg sulfamethoxazole) orally every 12 hours.
None Documented
None Documented
Sulfacetamide: 6-8 hours (prolonged in renal impairment). Prednisolone: 2-4 hours (terminal half-life). Clinically, systemic effects may persist longer due to tissue distribution.
SMX: 9-11 hours (terminal); TMP: 8-10 hours; prolonged in renal impairment (creatinine clearance <30 mL/min: up to 20-30 hours for both).
Renal excretion of unchanged sulfacetamide (60-75%) and prednisolone metabolites (primarily conjugated); minimal biliary/fecal elimination (<10% for each).
Renal: 50-70% of total sulfamethoxazole (SMX) and 30% of trimethoprim (TMP) as unchanged drug via glomerular filtration and tubular secretion; 20-40% of SMX as N4-acetylated metabolite; biliary excretion accounts for <5%.
Category A/B
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic